HC Wainwright & Co. Reiterates Buy on United Therapeutics, Maintains $300 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on United Therapeutics (NASDAQ:UTHR), maintaining a $300 price target. This reaffirmation of the company's stock rating and price target suggests a positive outlook on United Therapeutics' future performance.
February 22, 2024 | 11:48 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on United Therapeutics, with a maintained price target of $300, indicating a positive outlook on the company's stock.
The reiteration of a Buy rating and the maintenance of a $300 price target by a reputable analyst suggests a strong confidence in United Therapeutics' future performance. This endorsement is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100